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Eco Health – One Health  
• One Health is the collaborative effort of multiple disciplines 
working locally, nationally, and globally, to address critical 
challenges and attain optimal health for people, domestic 
animals, wildlife, and our environment  
 One Health Commission (http://www.onehealthcommission.org/ )  
 
• The One Health concept is a worldwide strategy for expanding 
interdisciplinary collaborations and communications in all 
aspects of health care for humans and animals. One Health 
Initiative (http://onehealthinitiative.com/)  
Broader thinking - OneHealth 
Eco Health – One Health  
• Ecosystem approaches to public health issues acknowledge the complex, 
systemic nature of public health and environmental issues, and the 
inadequacy of conventional methodologies for dealing with them. David 
Walter-Toews, University of Guelph  
 
• The Ecohealth approach focuses above all on the place of human beings 
within their environment. It recognizes that there are inextricable links 
between humans and their biophysical, social, and economic environments, 
and that these links are reflected in a population's state of health. 
International Development Research Centre (IDRC) 
 
• EcoHealth is an emerging field of study researching how changes in the 
earth’s ecoszstems affect human health. It has many prospects. EcoHealth 
examines changes in the biological, physical, social and economic 
environments and relates these changes to human health. Wikipedia.  
Broader thinking - EcoHealth 
v OneHealth 
• Definitions open to debate: range from quite rigid to 
very flexible; issues of branding 
• One-Health – biomedical focus: human + animal + 
wildlife; 
• One-Health: focus on communicable diseases 
• One-Health: operational / strategy  
• EcoHealth: environment & socio-economic aspects – 
pioneered outside ‘traditional’ health 
• EcoHealth: communicable & non-communicable 
diseases (dioxin; heavy metal toxicity) 
• Eco-Health: academic / research / complexity 
 
 
Compare / Contrast 
Eco Health – One Health  
 
 
Eco Health 
Complexity focus 
System thinking 
Pioneered by IDRC 
 
 
‘Bottom Up’  
Vets, Medics,  
epidemiologists,  
ecologists, social scientists,  
philosophers, indigenous  
perspectives, etc.  
Eco health 
One Health 
Integrated  approach 
One Health 
Schwabe‘s One Medicine 
One world/One Medicine 
 
More quantitative 
 
Veterinarians, medics, some 
ecologists 
 
Currently institutionalized 
 
Rather ‘Top down’  
Compare / Contrast 
Adapted from Karen Morison, University of Guelph 
EcoZD: Location of Project Activities 
 
 
Leptospirosis in community and abattoirs 
 
Rabies control and prevention 
 
Hygiene in small-scale poultry 
slaughterhouses (2 countries) 
Zoonotic causes of acute diarrhoea 
EcoHealth Resource Centre at Gadjah Mada 
University 
Increased risk of brucellosis and 
toxoplasmosis 
Prevalence of priority pig zoonoses 
EcoHealth Resource Centre at Chiang Mai 
University 
Challenges & Solutions 
 
 
Challenges 
• Accepting novel ‘EcoHealth’ 
paradigm and fostering trans-
disciplinary collaboration (some 
countries rigid mechanism 
including financial mechanisms) 
 
• Limited capacity within disciplines 
eg proposal writing, epidemiology, 
dissemination (journal articles, 
policy, IEC) 
• Competition with other 
projects/initiatives/’paradigm (One 
Health) 
 
• Sustainability of EcoHealth (One 
Health) approach 
 
5 year project cycle assisted, learning by 
doing approach gives first-hand experience 
using country priorities not donor ones 
Plans for all countries to disseminate 
approach and findings to research 
community, policy makers and communities 
Mentoring by ILRI researchers & technical 
experts provided real-time support 
according to needs; EcoHealth(One Health) 
Resource Centres for regional training and 
advocacy 
Teams/members were encouraged to be 
part of other initiatives; some team members 
drafted & submitted multi-country proposal 
to APEIR 
Ownership by teams: they chose the priority 
and conducted the research 
Further funding cycle(s) essential: 10+ years 
to institutionalise 
 
Solutions 
1. ILRI EcoZD project:  
 A participatory EcoHealth study of smallholder 
pig system in lowland and upland of Lao PDR 
2. ACIAR project: (funded by Australian Gov.) 
 Smallholder Pig System Project  
 
Purpose: To conduct baseline seroprevalence 
surveys of key pig diseases and pig related 
zoonoses and evaluate public health risks of 
pig-raising & pork consumption in one upland 
and one lowland province in Lao PDR  
ILRI/ACIAR supported - Lao  Projects 
 
Background/ rationale:  
 
- Smallholder pigs owned by 50-
70% of village HH. 
 
- No prior epidemiological 
prevalence surveys and risk 
analysis.   
 
- Regional increase in zoonoses 
and increasing disease outbreaks 
 
- Health and production risks.  
ILRI/ACIAR supported - Lao  Projects 
Research methodology 
A cross-sectional data collection including 
blood sampling from HUMAN and PIGS with 
questionnaire survey for risk factors. 
3 sets of Questionnaires 
Village head to get general village 
information 
Human  
Pig owners 
Training and field data collection: 
Introduction of the principle on EcoHealth 
with participatory sessions in teams that 
included 
 
 Introduction of the project, diseases and 
known zoonoses risks 
 
  Conducting practice random sampling, 
questionnaire interviews 
 
How to collect pig and human blood 
samples under ethical conditions. 
Study designs: 
               
Select 2 provinces Each 
province:  
30 Villages -sampled each 
15 Persons per village 
15 Pigs per village 
Study designs: 
               Multistage random sampling 
  random selection of 
village: PPP:Villages are 
randomly sampled weighted 
by human population 
  random selection of HH 
  random selection of 
individuals 
 Humans:   
 JEV,  
 Hep E,  
 Taenia /Cysticercosis  
 Trichinella 
 
 Pigs:   
 JEV, Hep E, Trichinella,  
 CSF,  
 PRRS,  
 Erysipelas,  
 FMD (Types O, A and Asia 1) 
 
• Structuring sampling frames for humans 
and pigs  
• Sampling based primarily on human population 
(not pig population) 
• Ethical issues  
 informed and signed consent forms for human 
participants 
 individual results within each village not 
identified by household names 
Appropriate modest health practical gifts to 
participating households 
Village level feedback of overall results 
Group meeting with 
villagers for 
Introduction 
• Interview of 
selected HH 
before blood 
sampling 
Blood sampling from 
pigs 
• Data entry and manipulation using new web 
based program: SurVet 
• Data analysis on Stata program 
Data Managenent 
Results  
Number of pig and Human sampled 
Study location Human Pig 
ILRI Luangprabang 
(north) 
447 310 
ILRI Savannakhet 
(South) 
435 365 
ACIAR/ SPSP 
(North) 
140 91 
Total 1022 766 
Sample test  
All tests carried out in Laos using commercial kits 
Human samples were tested  NCLE 
Pig sample    NAHC 
Results: Crude Sero-prevalence   
* Prevalence data reported above has not been adjusted for 
population weighting factors 
      
Disease Humans Pigs 
JEV  IgM 4.4% 8.5%  
JEV  IgG 75.2% 
Hep E  IgG 64%   61.4% 
Trichinella  47.3% 13.7% 
Taenia solium  IgG 2.9% 
Cysticercosis  IgG 4.7%  
Erysipelas 47.5% 
CSF 10.3% 
PRRS 8.2% 
FMD (ABC non-structural ELISA) 2.1% 
  
Results:  Human  Seroprevalence 
Antibody 
test 
Nth (n= 447) 
Crude Seroprev 
Sth (n = 435) Crude 
Seroprev 
 
JEV IgM* 
 
4.9%  
 
6.0% 
 
HEV IgG 
 
50.0% 
 
77.9% 
 
Trich IgG 
 
55.9% 
 
37.5% 
 Results  Pig Seroprevalence 
Antibody test Nth (n= 310) Crude 
Seroprev  
Sth (n= 365) Crude 
Seroprev 
JEV IgG 75.4% 81.8% 
JEV IgM 12.2% 6.7% 
HEV 81.9% 50.0% 
Trich  13.5% 9.0% 
CSF 7.4% 14.7% 
PRRS 11.3% 9.6% 
Erysipelas 63.5% 30.2% 
FMD 2.0% 2.8% 
Human and Pig Hepatitis E Sero-prevalence Results 
 
 
 
           Combined Human         Combined Pig 
 Prev  61.4%                       Prev 64.0% 
North – Upland 
 
 
 
 
 
 
South- Lowland  
                      50.00%   81.9% 
            77.9%             50.00% 
 Significant level of exposure of tested diseases were 
found in this study 
 Detailed risk related analysis have been done just only 
for HEV 
 Similar data analysis and interpretation for other 
diseases to be done  
 Using collected serums to test for other diseases 
 Risk reduction PA 
 Validation of test  
  
 
Discussion and recommendation 
Further use of ILRI-EcoZD serum bank 
• Serum stored from both pigs and people (NAHL/NCLE) 
• Other zoonoses of potential interest 
• Coxiella (Q fever) 
• Brucella 
• Joint laboratory activities to process samples and gain further 
insight into both these pathogens – though anticipate low 
prevalance/detection in pigs 
 
Subtitile 
Taenia solium: 
Baseline Survey Results and 
Intervention Options  
 
Anna Okello BVSc PhD  
Smallholder Pig Systems  
In-country Project Co-ordinator  
Life Cycle T. solium 
Taenia/Cysticercosis Complex:  
The Village Perspective 
• Free-range pigs 
• Poor latrine provision 
• Informal slaughter (especially for 
ceremonies) 
• Raw pork consumption 
• Low animal/human health inputs 
• Unknown cattle status 
• Unknown  dog status 
Human Health Implications of 
T. solium 
• Neurocysticercosis = leading cause 
of acquired epilepsy in the 
developing world 
• Responsible for approximately 5-
3,000 DALYs lost/year globally 
• Epilepsy highly stigmatised 
• MDA Interventions to control 
taeniasis also has impact on other 
NTDs (e.g shistosomiasis, STH)   
CONTROL OF T. solium  = 
opportunity to address 
several NTDs at the same 
time 
PACKAGED INTERVENTIONS 
 
Image from; http://www.cmaj.ca/content/180/6/639.full 
2011 EcoZD (ILRI/ACIAR) Human Taeniasis Prevalence 
2.9% (some hot-spots) 
  
2011 EcoZD (ILRI/ACIARI) Human Cysticercosis 
Prevalence 4.7% (some hot-spots) 
  
2013: Work-up in Om Phalong village to confirm 
high prevalence via ANTIGEN TESTING 
 
• 26% (CI 18-35) taeniasis (30/115) –copro-Ag ELISA 
• 30% (CI 9-61) cysticercosis (4/13) – serum-Ag ELISA 
→ Hyper-endemic status and active human cysticercosis  
 
Questionnaire data: Significant (p<0.05) findings (univariate 
analysis only) 
• Age [t.test p>0.0001] 
• Male [OR = 3.16] 
• No. times raw blood consumed per month [t.test p=0.03] 
• No. pigs kept [t.test p=0.0009] 
• Pigs kept confined in dry season , confinement = protective [OR = 0.27] 
• Contact with dogs (play)  = protective [OR = 0.27] 
• Knowledge of tapeworm from raw pork = protective [OR = 0.22] 
  
 
Plan: One Health Approach  
• Treat Humans: Mass Drug Administration (Niclosamide 
+ Albendazole) – MOH/WHO – Month 0, 12 
• Treat Pigs in 1st year of life: Vaccination (TSOL18) + 
oxfendazole – ACIAR -  every 4 months for 3 treatments 
• Human Behaviour Change – KAP analysis important 
• Policy – Economic analysis plus Proof of Scientific 
concept  
 CHALLENGES OPPORTUNITIES 
Sustained political commitment required Timing good – WHO 2102 NTD Roadmap, WHA  
Resolution 66.12 on NTDs May 2013 
Isolation  - logistics increase difficulty Isolation – As good as “closed” system for purposes of 
testing models  
Incoming slaughtered animals – not entirely “closed” 
situation  
Best chance at real impact  in this village  
Bringing all actors together in a One Health space – 
transdisciplinary and multi-sectoral 
2020 and beyond – Lao to be a regional leader in 
cysticercosis control 
Intervention Monitoring   
Porcine cysticercosis 
•Human sentinels – repeat MDA at 12 months – Oct 
2014  
•Buy & post-mortem pigs – high # required 
Human cysticercosis 
•Serum Antigen ELISA – fingerprick sampling 
development, however focus is to decrease human 
taeniasis   
Human taeniasis 
•Faecal monitoring – post MDA treatment as must 
be combined with safe disposal 
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